Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platforms

Landing AI的LandingLens™视觉检测软件平台被Ligand Pharmaceuticals选用,进一步赋能Omniab®和Xploration™抗体发现平台

2021-07-30 03:30:08 BioSpace


PALO ALTO, Calif., July 28, 2021 /PRNewswire/ -- Landing AI™ announced today a software licensing agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to incorporate LandingLens™ into Ligand's OmniAb® and xPloration™ antibody discovery platforms. LandingLens™ is a software platform that provides an end-to-end workflow to build, iterate and operationalize AI-powered visual inspection solutions. The new AI-driven tools further improve Ligand's high-throughput single B cell screening accuracy and throughput in a variety of complex biological assays, potentially increasing the yield of antibodies with desirable properties in even less time.  "Landing AI, under the leadership of world-renowned AI pioneer Andrew Ng, is a proven and trusted partner in empowering their customers to realize the business value of computer vision," says Bob Chen, Ph.D., Director, Systems Engineering with Ligand Pharmaceuticals. "We selected Landing AI because of the company's unique data-centric approach that puts getting high-quality data at the heart of AI development. Notably, the LandingLens™ software platform provides a host of specifically designed data preparation tools and capabilities that allow us to generate accurate and consistent datasets that we can iterate over time to continuously improve our existing AI systems."  "AI and deep learning have emerged as powerful technologies to enable a variety of vision-based applications. We are excited to enter into this partnership with Ligand Pharmaceuticals and are committed to offering the best tools to help our customers unlock the promise of AI," said John Reuter, Vice President of Sales at Landing AI. About OmniAb® The OmniAb antibody discovery platform provides Ligand's biopharmaceutical industry partners access to the world's most advanced antibody repertoires and screening technologies to enable unparalleled discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI) of Ligand's proprietary transgenic animals including OmniRat, OmniChicken and OmniMouse, each capable of generating high-quality fully human antibodies that have been optimized naturally through in vivo affinity maturation. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through AI-enhanced antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. The OmniAb suite of technologies and differentiating AI and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing antibody discovery needs of the global biopharmaceutical industry. About Ligand Pharmaceuticals Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand's business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Ligand's business model is based on doing what Ligand does best: drug discovery, early-stage drug development, product reformulation and partnering. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand's OmniAb® technology platform is a patent-protected technology stack used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand's Pelican® Expression Technology is a robust, validated, cost-effective and scalable approach to recombinant protein production, and is especially well-suited for complex, large-scale protein production that cannot be made by more traditional systems. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Gilead Sciences and Baxter International.  About Landing AI Landing AI™ empowers customers to realize the business and operational value of computer vision using enablement tools. The company's flagship product is LandingLens™, an enterprise MLOps platform that offers end-to-end workflow to build, iterate and operationalize AI powered visual inspection solutions. With data quality being a key to the success of production AI systems, LandingLens™ is equipped with a host of specially designed data preparation tools and workflows that help users achieve optimal data accuracy and consistency. Founded by Dr. Andrew Ng, co-founder of Coursera, former chief scientist of Baidu, and founding lead of Google Brain and guided by a data-centric AI approach, Landing AI is uniquely positioned to help companies successfully move their AI projects from proof-of-concept to full-scale production.  Contact: View original content: SOURCE
加州帕洛阿尔托2021年7月28日电/PRNewswire/--蓝鼎AI™今天宣布与Ligand Pharmaceuticals Incorporated(纳斯达克代码:LGND)达成软件许可协议,将LandingLens™纳入Ligand的Omniab®和Xploration™抗体发现平台。LandingLens™是一个提供端到端工作流的软件平台,以构建、迭代和操作人工智能驱动的视觉检测解决方案。 新的人工智能驱动工具进一步提高了配体在各种复杂生物检测中的高通量单个B细胞筛选精度和通量,潜在地在更短的时间内提高具有理想性质的抗体产量。 Ligand Pharmaceuticals系统工程总监Bob Chen博士表示:“在全球知名人工智能先驱吴恩达(Andrew Ng)的领导下,Landing AI是一个被证明值得信赖的合作伙伴,能够帮助客户实现计算机视觉的商业价值。”“我们选择Landing AI,是因为该公司独特的以数据为中心的方法,将获取高质量数据置于AI开发的核心。值得注意的是,LandingLens™软件平台提供了一系列专门设计的数据准备工具和能力,允许我们生成准确和一致的数据集,我们可以随着时间的推移迭代这些数据集,以不断改进现有的AI系统。” Landing AI销售副总裁John Reuter表示:“人工智能和深度学习已经成为支持各种基于视觉的应用的强大技术。我们很高兴与Ligand Pharmaceuticals达成合作关系,并致力于提供最好的工具来帮助我们的客户实现人工智能的承诺。” 关于Omniab® OmniAb抗体发现平台为Ligand的生物制药行业合作伙伴提供了获得世界上最先进的抗体库和筛选技术的机会,从而能够发现无与伦比的下一代治疗方法。OmniAb平台的核心是Ligand专有转基因动物的生物智能™(BI),包括OmniRat、OmniChicken和OmniMouse,每个动物都能够产生高质量的全人抗体,这些抗体通过体内亲和成熟自然优化。OmniFlic(转基因大鼠)和OmniClic(转基因鸡)通过一种常见的轻链方法解决了工业对双特异性抗体应用的需求,OmniTaur具有牛抗体的独特结构属性,用于复杂的靶点。OmniAb动物包括行业中最多样化的宿主系统,通过人工智能增强的抗原设计和免疫方法,配合高通量基于微流控的单个B细胞筛选和下一代测序数据集的深度计算分析,它们得到了最佳的杠杆作用,以识别具有优越性能和可发展特性的完全人类抗体。OmniAb系列技术以及区分AI和BI的特性结合在一起,为全球生物制药行业日益增长的抗体发现需求提供高效和可定制的端到端解决方案。 关于配体药物 Ligand是一家创收的生物制药公司,专注于开发或收购帮助制药公司发现和开发药物的技术。Ligand的商业模式为股东创造价值,提供多样化的生物技术和医药产品收入流,并得到高效和低公司成本结构的支持。Ligand的目标是为投资者提供一个机会,以一种有利可图、多样化和风险较低的业务参与生物技术行业的承诺,而不是一个典型的生物技术公司。Ligand的商业模式是基于做Ligand最擅长的事情:药物发现、早期药物开发、产品重组和合作。Ligand与其他制药公司合作,利用他们最擅长的(后期开发、监管管理和商业化)来最终创造我们的收入。Ligand的Omniab®技术平台是一个受专利保护的技术栈,用于发现全人单特异性和双特异性治疗抗体。Captisol平台技术是一种受专利保护的化学修饰环糊精,其结构旨在优化药物的溶解度和稳定性。Ligand的Pelican®表达技术是一种稳健的、经过验证的、成本有效的和可扩展的重组蛋白生产方法,特别适合于更传统的系统无法实现的复杂的、大规模的蛋白生产。Ligand已与包括安进、默克、辉瑞、赛诺菲、杨森、武田、吉利德科学和百特国际在内的世界领先制药公司建立了多个联盟、许可证和其他业务关系。 关于落地AI 落地AI™赋能客户,利用赋能工具实现计算机视觉的业务和运营价值。该公司的旗舰产品是LandingLens™,这是一个企业MLOps平台,提供端到端的工作流来构建、迭代和运营AI驱动的视觉检测解决方案。数据质量是生产AI系统成功的关键,LandingLens™配备了一系列专门设计的数据准备工具和工作流程,帮助用户实现最佳的数据准确性和一致性。由Coursera联合创始人、百度前首席科学家、谷歌大脑创始负责人吴恩达博士创立,以数据为中心的AI方式为指导,Landing AI的独特定位是帮助公司成功将其AI项目从概念验证推向全面生产。 联系人: 查看原始内容: 来源